Tags

Type your tag names separated by a space and hit enter

Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Laryngoscope. 2006 Mar; 116(3):407-12.L

Abstract

OBJECTIVES

Nasal vaccination is an effective therapeutic regimen for preventing otitis media. Since cholera toxin (CT) is toxic, an alternative adjuvant is required for the development of a nasal vaccine. The efficacy of CpG oligodeoxynucleotide (ODN) as a mucosal adjuvant was examined.

METHODS

Mice were immunized intranasally with P6 protein of non-typeable Haemophilus influenzae (NTHi) and adjuvant, CT, or CpG ODN, and P6-specific antibody responses were examined. The expression of P6-specific cytokine mRNA in splenic CD4 T cells was also determined. In addition, NTHi challenges were performed and the NTHi was quantified in nasal washes.

RESULTS

P6-specific IgA in nasal wash and serum IgG titers were elevated significantly after nasal immunization. The IgG1/IgG2a ratio in serum from P6+CpG-immunized mice was less than that of P6+CT-immunized mice. Although IL-6 was expression similarly in both groups, IFN-gamma expression was greater in P6+CpG-immunized mice than in P6+CT-immunized mice. Enhanced clearance of NTHi from the nasopharynx was also shown equally in both groups.

CONCLUSION

These results indicate that CpG ODN might be an effective mucosal adjuvant, acting by mechanisms that are different from CT. These findings suggest that nasal vaccination with P6 and CpG ODN might be an effective regimen for the induction of NTHi-specific protective immunity.

Authors+Show Affiliations

From the Department of Otolaryngology (n.a., s.k., t.h., m.e., m.s.), Oita University Faculty of Medicine, 1-1 Idaigaoka, Hazama-machi, Yufu, Oita, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16540899

Citation

Abe, Nobuyuki, et al. "Nasal Vaccination With CpG Oligodeoxynucleotide Induces Protective Immunity Against Non-typeable Haemophilus Influenzae in the Nasopharynx." The Laryngoscope, vol. 116, no. 3, 2006, pp. 407-12.
Abe N, Kodama S, Hirano T, et al. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope. 2006;116(3):407-12.
Abe, N., Kodama, S., Hirano, T., Eto, M., & Suzuki, M. (2006). Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. The Laryngoscope, 116(3), 407-12.
Abe N, et al. Nasal Vaccination With CpG Oligodeoxynucleotide Induces Protective Immunity Against Non-typeable Haemophilus Influenzae in the Nasopharynx. Laryngoscope. 2006;116(3):407-12. PubMed PMID: 16540899.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. AU - Abe,Nobuyuki, AU - Kodama,Satoru, AU - Hirano,Takashi, AU - Eto,Mayumi, AU - Suzuki,Masashi, PY - 2006/3/17/pubmed PY - 2006/4/7/medline PY - 2006/3/17/entrez SP - 407 EP - 12 JF - The Laryngoscope JO - Laryngoscope VL - 116 IS - 3 N2 - OBJECTIVES: Nasal vaccination is an effective therapeutic regimen for preventing otitis media. Since cholera toxin (CT) is toxic, an alternative adjuvant is required for the development of a nasal vaccine. The efficacy of CpG oligodeoxynucleotide (ODN) as a mucosal adjuvant was examined. METHODS: Mice were immunized intranasally with P6 protein of non-typeable Haemophilus influenzae (NTHi) and adjuvant, CT, or CpG ODN, and P6-specific antibody responses were examined. The expression of P6-specific cytokine mRNA in splenic CD4 T cells was also determined. In addition, NTHi challenges were performed and the NTHi was quantified in nasal washes. RESULTS: P6-specific IgA in nasal wash and serum IgG titers were elevated significantly after nasal immunization. The IgG1/IgG2a ratio in serum from P6+CpG-immunized mice was less than that of P6+CT-immunized mice. Although IL-6 was expression similarly in both groups, IFN-gamma expression was greater in P6+CpG-immunized mice than in P6+CT-immunized mice. Enhanced clearance of NTHi from the nasopharynx was also shown equally in both groups. CONCLUSION: These results indicate that CpG ODN might be an effective mucosal adjuvant, acting by mechanisms that are different from CT. These findings suggest that nasal vaccination with P6 and CpG ODN might be an effective regimen for the induction of NTHi-specific protective immunity. SN - 0023-852X UR - https://www.unboundmedicine.com/medline/citation/16540899/Nasal_vaccination_with_CpG_oligodeoxynucleotide_induces_protective_immunity_against_non_typeable_Haemophilus_influenzae_in_the_nasopharynx_ DB - PRIME DP - Unbound Medicine ER -